MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production

PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences

Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn Life Sciences AWKNF.

“We’ve been working with the Awakn team for several months now, to ensure they have all the material needed for their development efforts,” said PharmAla’s CEO Nick Kadysh. He added that both companies “share a bit of founding history,” referring to Prof. David Nutt, founding board member of PharmAla who left the board to become Awakn’s CRO. In this sense, he says, it’s “completely fitting” to become Awakn’s supplier of both engineering-grade and GMP LaNeo MDMA towards growing its R&D program. 

Awakn CEO Anthony Tennyson said that the company is running a feasibility study to assess and to potentially develop “a market-ready proprietary formulation and optimized delivery route for MDMA,” which seeks to reduce treatment time.

“Having a trusted partner like PharmAla as our API supplier will reduce risk and potentially increase the probability of success for this program,” Tennyson said.

HYTN Innovations Intends To Expand Its Canadian License To Manufacture Several Psychedelics

Vancouver-based psychedelics company HYTN Innovations Inc. submitted an amendment to its Controlled Drugs and Substances (CDS) dealer’s license with Health Canada which, if approved, would allow the company to produce compounds such as MDMA, ketamine, LSD, cocaine, and other lesser-known compounds in addition to cannabinoids and psilocybin. 

The company also entered the review stage for both a Drug Establishment License (DEL) under the Food and Drugs Act, and a Precursors License under the Controlled Drugs and Substances Act, all of which reinforce the company's goal to expand its product offerings under regulatory compliance.

See also: HYTN To Complement Cannabis Line With Psilocybin-Based Products, Obtains Controlled Drugs And Substances Dealer's License

The company previously sold cannabis-derived cannabinoids formatted into novel medicines through Australia’s Therapeutic Goods Administration (TGA.)

See also: Australia's Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions

HYTN's COO Jason Broome said the achievement demonstrates “the strength and workability” of HYTN's quality systems and operational controls, noting that the company is well-equipped to act as a supplier for clinical trials and the Special Access Program.

Photo: Benzinga edit with photo by Yuriy Golub and Bacsica on Shutterstock.